Xtant Medical (NYSE: XTNT) turns profit in 2025, guides 2026 revenue to $95–99M
Rhea-AI Filing Summary
Xtant Medical Holdings, Inc. reported a strong turnaround for 2025, shifting to profitability while reshaping its portfolio. Full-year 2025 revenue reached $133.9–$134.0 million, up about 14% from 2024, driven by higher license revenue and growth in its core biologics business.
Net income for 2025 improved to $5.0 million, or $0.03–$0.04 per share, compared with a prior-year net loss of $16.5 million. Non-GAAP adjusted EBITDA rose to $16.3 million from a loss of $2.3 million, reflecting better gross margins of 62.9% and lower operating expenses. Cash and restricted cash increased to $17.3 million at year-end, supported by divesting non-core Coflex/CoFix assets and an international hardware business.
For 2026, the company expects revenue between $95 million and $99 million, as organic growth in higher-margin biologics is offset by the December 2025 divestitures and the end of 2025 license revenue streams. Management highlighted a term loan balance of $11.2 million and a current cash position above $22 million, and it expects to be free cash flow positive in 2026 without raising additional outside capital.
Positive
- None.
Negative
- None.
Insights
Xtant posts profitable 2025, but 2026 revenue will reset lower after divestitures.
Xtant Medical delivered a clear inflection in 2025: revenue grew to $133.9M–$134.0M, up 14%, and net income improved to $5.0M from a significant prior-year loss. Non-GAAP adjusted EBITDA reached $16.3M, aided by a gross margin increase to 62.9% and lower operating expenses.
The business mix changed meaningfully. Management sold non-core Coflex/CoFix and international hardware operations to Companion Spine and benefited from a short-term license and royalty opportunity in advanced wound care. These moves boosted 2025 revenue and cash but remove lower-margin contributions going forward.
For 2026, guidance of $95M–$99M revenue implies a sizable step down from 2025 as divested and license revenues roll off. However, the company ends 2025 with $17.3M in cash and restricted cash, over $22M currently, and a reduced term loan of $11.2M. Management expects 2026 free cash flow to be positive, with growth focused on higher-margin biologics and commercial investments.
8-K Event Classification
Key Figures
Key Terms
non-GAAP adjusted EBITDA financial
gross margin financial
divestiture financial
license revenue financial
term loan financial
free cash flow positive financial
Offering Details
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
| ||
| (Address of principal executive offices) | (Zip Code) |
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02 | Results of Operations and Financial Condition. |
On March 31, 2026, Xtant Medical Holdings, Inc. (the “Company”) announced its financial results for the three months and year ended December 31, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in Item 2.02 of this report (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any registration statement or other document filed by the Company under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly provided by specific reference in such a filing.
To supplement its consolidated financial statements prepared in accordance with United States generally accepted accounting principles (“GAAP”), the Company uses certain non-GAAP financial measures, such as non-GAAP adjusted EBITDA, which are included in the press release furnished as Exhibit 99.1 to this report. The Company defines non-GAAP adjusted EBITDA as net income (loss) from operations before depreciation and amortization expense; interest expense, net; and tax benefit (expense), and as further adjusted to add back in or exclude, non-cash compensation, divestiture/acquisition-related expenses, gain on divestiture, acquisition-related fair value adjustments, unrealized foreign currency translation gain or loss, and separation-related expenses, in each case as applicable.
The Company uses non-GAAP adjusted EBITDA in making operating decisions because it believes this measure provides meaningful supplemental information regarding its core operational performance. Additionally, this measure gives the Company a better understanding of how it should invest in sales and marketing and research and development activities and how it should allocate resources to both ongoing and prospective business initiatives. The Company also uses non-GAAP adjusted EBITDA to help make budgeting and spending decisions, for example, among sales and marketing expenses, general and administrative expenses, and research and development expenses. Additionally, the Company believes its use of non-GAAP adjusted EBITDA facilitates management’s internal comparisons to historical operating results by factoring out potential differences caused by charges not related to its regular, ongoing business, including, without limitation, non-cash charges and certain large and unpredictable charges and gains.
As described above, the Company excludes the effect of the following items from its non-GAAP adjusted EBITDA for the following reasons:
Non-cash compensation. The Company excludes non-cash compensation, which is a non-cash charge related to equity awards granted by the Company. Although non-cash compensation is a recurring charge to the Company’s operations, management has excluded it because it relies on valuations based on future events, such as the market price of the Company’s common stock, that are difficult to predict and are affected by market factors that are largely not within the control of the Company. Thus, management believes that excluding non-cash compensation facilitates comparisons of the Company’s operational performance in different periods, as well as with similarly determined non-GAAP financial measures of comparable companies.
Divestiture/acquisition-related expenses. The Company excludes expenses directly related to the Company’s divestiture of its non-core Coflex/CoFix assets and the international hardware business and its acquisitions and integration into the Company from non-GAAP adjusted EBITDA primarily because such expenses are not reflective of the Company’s ongoing operating results and are not used by management to assess the core profitability of the Company’s business operations. These expenses include legal and accounting fees and transition related services and are not considered normal, recurring, cash operating expenses necessary to operate the Company’s business. The Company further believes that excluding this item from its non-GAAP results is useful to investors in that it allows for period-over-period comparability.
Gain on divestiture. The Company excludes gain on divestiture from non-GAAP adjusted EBITDA primarily because such an item is not reflective of the Company’s ongoing operating results and is not used by management to assess the core profitability of the Company’s business operations. The Company further believes that excluding this item from its non-GAAP results is useful to investors in that it allows for period-over-period comparability.
Acquisition-related fair value adjustments. The Company excludes acquisition-related fair value adjustments from non-GAAP adjusted EBITDA primarily because such adjustments are not reflective of the Company’s ongoing operating results and are not used by management to assess the core profitability of the Company’s business operations. The Company further believes that excluding this item from its non-GAAP results is useful to investors in that it allows for period-over-period comparability.
Unrealized foreign currency translation gain or loss. The Company excludes unrealized foreign currency translation gain or loss, as applicable, from non-GAAP adjusted EBITDA primarily because such gain or loss is not reflective of the Company’s ongoing operating results and is not used by management to assess the core profitability of the Company’s business operations. The Company further believes that excluding this item from its non-GAAP results is useful to investors in that it allows for period-over-period comparability.
Separation-related expenses. The Company excludes separation-related expenses primarily because such expenses are not reflective of the Company’s ongoing operating results and are not used by management to assess the core profitability of the Company’s business operations. The Company further believes that excluding this item from its non-GAAP results is useful to investors in that it allows for period over-period comparability.
Non-GAAP adjusted EBITDA is reconciled to net income (loss), the most directly comparable GAAP measure in the press release. The Company also presents in the press release EBITDA as a percentage of total revenue and adjusted EBITDA as a percentage of total revenue and reconciles these two non-GAAP measures in the press release to net income (loss) as a percentage of total revenue.
Non-GAAP financial measures are not in accordance with, or an alternative for, GAAP measures and may be different from non-GAAP financial measures used by other companies. In addition, non-GAAP financial measures are not based on any comprehensive or standard set of accounting rules or principles. Accordingly, the calculation of the Company’s non-GAAP financial measures may differ from the definitions of other companies using the same or similar names, limiting, to some extent, the usefulness of such measures for comparison purposes. Non-GAAP financial measures have limitations in that they do not reflect all of the amounts associated with the Company’s financial results as determined in accordance with GAAP. Non-GAAP financial measures should only be used to evaluate the Company’s financial results in conjunction with the corresponding GAAP measures. Accordingly, the Company qualifies its use of non-GAAP financial information in a statement when non-GAAP financial information is presented.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit No. | Description | |
| 99.1 | Press Release of Xtant Medical Holdings, Inc. dated March 31, 2026 entitled “Xtant Medical Reports Fourth Quarter and Full-Year 2025 Financial Results” (furnished herewith) | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| XTANT MEDICAL HOLDINGS, INC. | ||
| By: | /s/ Scott C. Neils | |
| Scott C. Neils | ||
| Chief Financial Officer | ||
Date: March 31, 2026
Exhibit 99.1
Xtant Medical Reports Fourth Quarter and Full-Year 2025 Financial Results
Full year 2025 revenue totals $133.9 million, an increase of 14% year-over-year
Xtant delivers positive net income, adjusted EBITDA and operating cash flow
Total cash of $17.3 million as of December 31, 2025 with an additional $10.5 million received subsequent to year end related to divestiture
BELGRADE, Mont., March 31, 2026 — Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today reported financial and operating results for the fourth quarter and full-year ended December 31, 2025.
Fourth Quarter 2025 Financial Highlights
| ● | Revenue of $32.4 million, up approximately 3% compared to the prior year quarter |
| ◌ | Company’s earlier-than-anticipated closing of the Companion Spine transaction reduced fourth quarter 2025 revenue by an estimated $2.0 million |
| ● | Gross margin of 54.9% compared to 50.8% for the prior year quarter |
| ● | Net income of $0.1 million compared to a net loss of $3.2 million in the prior year quarter |
| ● | Non-GAAP adjusted EBITDA of $1.9 million compared to adjusted EBITDA of $0.4 million in the prior year quarter |
Full-Year 2025 Financial Highlights
| ● | Revenue of $134.0 million, up approximately 14% over the full-year 2024 |
| ● | Gross margin of 62.9%, compared to 58.2% for the full year 2024 |
| ● | Net income of $5.0 million, or $0.03 per diluted share, compared to a net loss of $16.5 million, or a net loss of $0.12 per basic and diluted share, for the full year 2024 |
| ● | Non-GAAP adjusted EBITDA of $16.3 million compared to an adjusted EBITDA loss of $2.3 million for the full year 2024 |
| ● | Net cash provided by operations of $12.5 million compared to net cash used in operations of $11.9 million for the full year 2024 |
Fourth Quarter 2025 and Recent Business Highlights
| ● | Completed the previously announced sale of Xtant’s non-core Coflex® and CoFix assets and its international hardware businesses to Companion Spine for a total sale price of $21.4 million in cash. |
| ● | Announced the commercial launch of its next-generation innovative synthetic bone graft in the nanOss line, Strata™. nanOss Strata is manufactured from hydroxycarbonapatite (HCA), a material with higher solubility than traditional hydroxyapatite (HA), the most commonly used synthetic material. |
| ● | Announced the commercial launch of CollagenX™, its bovine collagen particulate product for surgical wound closure designed to promote healing, prevent dehiscence, and help mitigate concerns related to surgical site infections. |
Sean Browne, President and CEO of Xtant Medical, stated, “Our fourth quarter 2025 caps a truly transformational year for Xtant, during which we meaningfully sharpened our focus on our core biologics business while driving the new product innovation for which we are known. Along the way, in 2025 we achieved profitability and cash flow generation, reflecting robust topline growth, targeted R&D investments, and prudent expense management. We also took advantage of a short-term license and royalty opportunity through our amnio line in the advanced wound care market. Those cash flows, along with the divestiture of certain non-core products and operations, provided Xtant with the capital to focus on internally developing our advanced biologics product lines, including new products released in 2025. With this foundation in place, we began to opportunistically add to our field sales force in the fourth quarter 2025 and into the first quarter of 2026 to improve our reach and leverage our outstanding contract portfolio and independent agent network.”
“Looking ahead to 2026, with the recent receipt of amounts previously outstanding under our note receivable from the Companion Spine transaction, we have increased our current cash position to over $22 million while reducing our term loan balance to $11.2 million. Given our significantly strengthened financial position, we do not see any need to raise additional outside capital to run our operations and we expect to be free cash flow positive in 2026. Moreover, this year we plan to lean into our strengths in biologics and invest in our commercial team to focus on profitably growing our core biologics business. With the substantial progress made in 2025, I am excited for this year and beyond,” Mr. Browne concluded.
Fourth Quarter and Full-Year 2025 Financial Results
Fourth quarter 2025 revenue grew 3% to $32.4 million, compared to $31.5 million for the same period in 2024. The increase is due primarily to higher license revenue, partly offset by one less month of Coflex and CoFix and related international hardware sales in 2025 as a result of the sale of those businesses to Companion Spine in early December. For the full year, total revenue of $134.0 million increased 14% over $117.3 million for the full year 2024.
Gross margin for the fourth quarter of 2025 was 54.9%, compared to 50.8% for the same period in 2024. For the full year 2025, gross margin was 62.9%, compared to 58.2% for the full year 2024. These increases were primarily attributable to sales mix and greater scale, partially offset by increased charges for excess and obsolete inventory, in particular, a $1.3 million charge related to excess and obsolete inventory associated with the launch of the Cortera® Fixation System.
Operating expenses for the fourth quarter of 2025 totaled $18.7 million, compared to $17.9 million for the fourth quarter of 2024. Full year 2025 total operating expenses were $77.0 million, compared to $80.3 million for the full year 2024. The increase in fourth quarter 2025 operating expenses was primarily due to increases in various compensation plans and the year-over-year decline was primarily driven by reduced commission expense.
Net income for the fourth quarter 2025 totaled $0.1 million, compared to a net loss of $3.2 million for the fourth quarter of 2024. For the full year 2025, net income was $5.0 million, or $0.03 per diluted share, compared to a net loss of $16.5 million, or a new loss of $0.12 per basic and diluted share, for the full year 2024.
Non-GAAP adjusted EBITDA for the fourth quarter of 2025 totaled $1.9 million, compared to adjusted EBITDA of $0.4 million for the same period in 2024. For the full year 2025, non-GAAP adjusted EBITDA was $16.3 million, compared to an adjusted EBITDA loss of $2.3 million for the full year 2024.
The Company defines adjusted EBITDA as net income/loss from operations before depreciation, amortization and interest income/expense and provision for income tax/benefit, and as further adjusted to add back in or exclude, as applicable, separation-related expenses, non-cash compensation, disposition/acquisition-related expense, acquisition-related fair value adjustments, gain on divestiture, and unrealized foreign currency translation gain or loss. A calculation and reconciliation of adjusted EBITDA to net income (loss) can be found in the attached financial tables.
As of December 31, 2025, the Company had $17.3 million of cash and cash equivalents compared to $6.2 million as of December 31, 2024. Cash as of December 31, 2025 excludes an additional $10.5 million received in February 2026 upon repayment of the unsecured promissory note issued by Companion Spine to Xtant in the divestiture transactions that closed in December 2025.
2026 Financial Guidance
The Company anticipates full-year 2026 revenue to be in the range of $95 million to $99 million. This outlook reflects anticipated organic growth in its core higher-margin biologics business, offset bythe impact of the Company’s December 2025 sale of non-core Coflex® and CoFix assets and its international hardware businesses to Companion Spine, as well as the cessation of license revenue related to the Q-Code and amniotic membrane agreements that the Company received in 2025.
Conference Call
Xtant Medical will host a webcast and conference call to discuss its fourth quarter and full-year 2025 financial and operating results at 8:30 am ET today, March 31, 2026.
To access the webcast: https://www.webcaster5.com/Webcast/Page/3039/53616
To access the conference call, dial 888-506-0062 (US) or 973-528-0011 (International) and reference Participant Access Code 581090.
A replay of the call will be available on the Investor section of the Company’s website at www.xtantmedical.com for a period of one year.
About Xtant Medical Holdings, Inc.
Xtant Medical’s mission of honoring the gift of donation so that our patients can live as full and complete a life as possible, is the driving force behind our company. Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics serving the chronic and surgical wound care and sports medicine markets, as well as spinal implant systems. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.
The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.
Non-GAAP Financial Measures
To supplement the Company’s consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures in this release, including adjusted EBITDA. Reconciliations of the non-GAAP financial measures used in this release to the most comparable GAAP measures for the respective periods can be found in tables later in this release. The Company’s management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company’s operations, period over period. Management uses the non-GAAP measures in this release internally for evaluation of the performance of the business, including the allocation of resources. Investors should consider non-GAAP financial measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as “intends,” ‘‘expects,’’ ‘‘anticipates,’’ ‘‘plans,’’ ‘‘believes,’’ ‘‘estimates,’’ “continue,” “future,” ‘‘will,’’ “potential,” “going forward,” “guidance,” similar expressions or the negative thereof, and the use of future dates. Forward-looking statements in this release include the Company’s full year 2026 revenue guidance, anticipated organic growth in its core higher-margin biologics business, need for no further capital to fund its operations and expectation to be free cash flow positive in 2026. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company’s future operating results, financial performance and need for additional capital; the success of the Company’s expanded field sales force to improve the Company’s reach and leverage its outstanding contract portfolio and independent agent network; the Company’s ability to become operationally self-sustaining and less reliant on third-party manufacturers and suppliers; risks associated with acquisitions and dispositions; its ability to implement successfully its future growth initiatives and risks associated therewith; possible future impairment charges to long-lived assets and goodwill and write-downs of excess and obsolete inventory; its ability to continue to innovate, develop and introduce new products and the success of those products; its ability to remain competitive; its ability to engage and retain new and existing independent distributors and agents and qualified sales and other personnel and its dependence on key independent agents for a significant portion of its revenue; the effect of inflation, elevated interest rates and other recessionary factors and supply chain disruptions; the effect of product sales mix changes on its financial results; the effect of government and third-party coverage and reimbursement for its products; its ability to obtain and maintain regulatory approvals and comply with government regulations; the effect of product liability claims and other litigation to which the Company may be subject; the effect of product recalls and defects; its ability to license intellectual property on commercially reasonable terms and to maintain any such licenses and its ability to obtain and protect its intellectual property and proprietary rights and operate without infringing the rights of others; its ability to service its debt, comply with debt covenants, and access additional indebtedness or financing on favorable terms or at all, if and when needed; and other factors described in its Annual Report on Form 10-K for the year ended December 31, 2025 to be filed with the Securities and Exchange Commission (SEC) on March 30, 2026. Investors are encouraged to read the Company’s filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement.
Investor Relations Contact:
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
-OR-
Rob Windsor
LifeSci Advisors
rwindsor@lifescipartners.com
— Tables Follow –
XTANT MEDICAL HOLDINGS, INC.
Consolidated Balance Sheets
(In thousands, except number of shares and par value)
As of December 31, 2025 | As of December 31, 2024 | |||||||
| ASSETS | ||||||||
| Current Assets: | ||||||||
| Cash and cash-equivalents | $ | 17,053 | $ | 6,199 | ||||
| Restricted cash | 275 | 22 | ||||||
| Trade accounts receivable, net of allowance for credit losses of $2,165 and $1,437, respectively | 17,803 | 20,660 | ||||||
| Inventories | 30,263 | 38,634 | ||||||
| Note receivable | 10,462 | — | ||||||
| Prepaid and other current assets | 2,389 | 1,601 | ||||||
| Total current assets | 78,245 | 67,116 | ||||||
| Property and equipment, net | 6,202 | 10,131 | ||||||
| Right of use asset, net | 3,192 | 829 | ||||||
| Goodwill | 6,074 | 7,302 | ||||||
| Intangible assets, net | 299 | 8,356 | ||||||
| Other assets | 133 | 103 | ||||||
| Total Assets | $ | 94,145 | $ | 93,837 | ||||
| LIABILITIES & STOCKHOLDERS’ EQUITY | ||||||||
| Current Liabilities: | ||||||||
| Accounts payable | $ | 3,844 | $ | 7,918 | ||||
| Accrued liabilities | 10,626 | 7,771 | ||||||
| Current portion of long-term debt | 3,500 | — | ||||||
| Current portion of lease liability | 622 | 703 | ||||||
| Current portion of finance lease obligations | 35 | 69 | ||||||
| Line of credit | 10,857 | 12,120 | ||||||
| Total current liabilities | 29,484 | 28,581 | ||||||
| Long-term Liabilities: | ||||||||
| Lease liability, net | 2,665 | 166 | ||||||
| Financing lease obligations, net | 12 | 47 | ||||||
| Long-term debt, plus premium and less issuance costs | 11,026 | 22,038 | ||||||
| Deferred tax liability | 5 | 42 | ||||||
| Total Liabilities | 43,192 | 50,874 | ||||||
| Commitments and Contingencies (Note 12) | — | — | ||||||
| Stockholders’ Equity: | ||||||||
| Preferred stock, $0.000001 par value; 10,000,000 shares authorized; no shares issued and outstanding | — | — | ||||||
| Common stock, $0.000001 par value; 300,000,000 shares authorized; 140,039,557 shares issued and outstanding as of December 31, 2025; 139,045,664 shares issued and outstanding as of December 31, 2024 | — | — | ||||||
| Additional paid-in capital | 305,439 | 302,738 | ||||||
| Accumulated other comprehensive income | — | (316 | ) | |||||
| Accumulated deficit | (254,486 | ) | (259,459 | ) | ||||
| Total Stockholders’ Equity | 50,953 | 42,963 | ||||||
| Total Liabilities & Stockholders’ Equity | $ | 94,145 | $ | 93,837 | ||||
XTANT MEDICAL HOLDINGS, INC.
Consolidated Statements of Operations
(Unaudited, in thousands, except number of shares and per share amounts)
Three Months Ended December 31, | Twelve Months Ended December 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Revenue | ||||||||||||||||
| Product revenue | $ | 27,712 | $ | 30,011 | $ | 115,204 | $ | 115,765 | ||||||||
| License revenue | 4,645 | 1,502 | 18,723 | 1,502 | ||||||||||||
| Total Revenue | 32,357 | 31,513 | 133,927 | 117,267 | ||||||||||||
| Cost of Sales | 14,603 | 15,489 | 49,654 | 49,051 | ||||||||||||
| Gross Profit | 17,754 | 16,024 | 84,273 | 68,216 | ||||||||||||
| Operating Expenses | ||||||||||||||||
| General and administrative | 7,293 | 5,700 | 29,375 | 28,691 | ||||||||||||
| Sales and marketing | 10,946 | 11,684 | 45,512 | 49,214 | ||||||||||||
| Research and development | 459 | 522 | 2,102 | 2,385 | ||||||||||||
| Total Operating Expenses | 18,698 | 17,906 | 76,989 | 80,290 | ||||||||||||
| Income (Loss) from Operations | (944 | ) | (1,882 | ) | 7,284 | (12,074 | ) | |||||||||
| Other Income (Expense) | ||||||||||||||||
| Interest expense | (718 | ) | (1,134 | ) | (3,671 | ) | (4,160 | ) | ||||||||
| Interest income | 94 | — | 94 | — | ||||||||||||
| Unrealized foreign currency translation (loss) gain | (206 | ) | (101 | ) | (60 | ) | 5 | |||||||||
| Gain on divestiture | 3,281 | — | 3,281 | — | ||||||||||||
| Other income (expense) | 91 | (27 | ) | 73 | (33 | ) | ||||||||||
| Total Other Income (Expense) | 2,542 | (1,262 | ) | (283 | ) | (4,188 | ) | |||||||||
| Net Income (Loss) from Operations Before Provision for Income Taxes | 1,598 | (3,144 | ) | 7,001 | (16,262 | ) | ||||||||||
| Provision for Income Taxes Current and Deferred | (1,541 | ) | (21 | ) | (2,028 | ) | (187 | ) | ||||||||
| Net Income (Loss) | $ | 57 | $ | (3,165 | ) | $ | 4,973 | $ | (16,449 | ) | ||||||
| Net Income (Loss) Per Share: | ||||||||||||||||
| Basic | $ | 0.00 | $ | (0.02 | ) | $ | 0.04 | $ | (0.12 | ) | ||||||
| Dilutive | $ | 0.00 | $ | (0.02 | ) | $ | 0.03 | $ | (0.12 | ) | ||||||
| Shares used in the computation: | ||||||||||||||||
| Basic | 139,826,783 | 138,977,615 | 139,531,791 | 133,665,075 | ||||||||||||
| Dilutive | 150,462,888 | 138,977,615 | 150,042,556 | 133,665,075 | ||||||||||||
XTANT MEDICAL HOLDINGS, INC.
Consolidated Statements of Cash Flows
(Unaudited, in thousands)
| Year Ended December 31, | ||||||||
| 2025 | 2024 | |||||||
| Operating activities: | ||||||||
| Net income (loss) | $ | 4,973 | $ | (16,449 | ) | |||
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | ||||||||
| Depreciation and amortization | 5,223 | 4,224 | ||||||
| Non-cash interest | 537 | 522 | ||||||
| Loss (gain) on sale of fixed assets | 251 | (264 | ) | |||||
| Stock-based compensation | 2,892 | 4,117 | ||||||
| Provision for reserve on accounts receivable | 1,404 | 823 | ||||||
| Provision for excess and obsolete inventory | 3,669 | 485 | ||||||
| Gain on sale to Companion | (3,281 | ) | — | |||||
| Other | (76 | ) | (5 | ) | ||||
| Changes in operating assets and liabilities, net of the effects of acquisitions: | ||||||||
| Trade accounts receivable | (591 | ) | (755 | ) | ||||
| Inventories | (1,999 | ) | (2,494 | ) | ||||
| Prepaid and other assets | (1,537 | ) | (218 | ) | ||||
| Accounts payable | (3,117 | ) | 1,033 | |||||
| Accrued liabilities | 4,198 | (2,915 | ) | |||||
| Net cash provided by (used in) operating activities | 12,546 | (11,896 | ) | |||||
| Investing activities: | ||||||||
| Purchases of property and equipment | (2,382 | ) | (4,113 | ) | ||||
| Proceeds from sale of fixed assets | 232 | 383 | ||||||
| Proceeds from sale to Companion, net of promissory note | 10,049 | — | ||||||
| Net cash provided by (used in) investing activities | 7,899 | (3,730 | ) | |||||
| Financing activities: | ||||||||
| Borrowings on line of credit | 100,066 | 112,640 | ||||||
| Repayments on line of credit | (101,329 | ) | (105,142 | ) | ||||
| Payments on long-term debt | (8,000 | ) | — | |||||
| Payments on financing leases | (67 | ) | (65 | ) | ||||
| Proceeds from private placement, net of issuance costs | (65 | ) | 4,456 | |||||
| Proceeds from issuance of long-term debt | — | 5,000 | ||||||
| Debt issuance costs | (49 | ) | (651 | ) | ||||
| Payment of taxes from withholding of common stock upon vesting and settlement of restricted stock units | (126 | ) | (178 | ) | ||||
| Proceeds from exercise of stock-based compensation | — | 13 | ||||||
| Net cash (used in) provided by financing activities | (9,570 | ) | 16,073 | |||||
| Effect of exchange rate changes on cash and cash equivalents and restricted cash | 232 | (149 | ) | |||||
| Net change in cash and cash equivalents and restricted cash | 11,107 | 298 | ||||||
| Cash and cash equivalents and restricted cash at beginning of year | 6,221 | 5,923 | ||||||
| Cash and cash equivalents and restricted cash at end of year | $ | 17,328 | $ | 6,221 | ||||
| Reconciliation of cash and cash equivalents and restricted cash reported in the consolidated balance sheets | ||||||||
| Cash and cash equivalents | $ | 17,053 | $ | 6,199 | ||||
| Restricted cash | 275 | 22 | ||||||
| Total cash and cash equivalents and restricted cash reported in the consolidated balance sheets | $ | 17,328 | $ | 6,221 | ||||
XTANT MEDICAL HOLDINGS, INC.
CALCULATION OF NON-GAAP CONSOLIDATED EBITDA AND ADJUSTED EBITDA
(in thousands)
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Net Income (Loss) | $ | 57 | $ | (3,165 | ) | $ | 4,973 | $ | (16,449 | ) | ||||||
| Depreciation and amortization | 1,819 | 1,148 | 5,223 | 4,224 | ||||||||||||
| Interest expense, net | 624 | 1,134 | 3,577 | 4,160 | ||||||||||||
| Tax expense | 1,541 | 21 | 2,028 | 187 | ||||||||||||
| Non-GAAP EBITDA | 4,041 | (862 | ) | 15,801 | (7,878 | ) | ||||||||||
| Net Income (Loss)/Total Revenue | 0.2 | % | -10.0 | % | 3.7 | % | -14.0 | % | ||||||||
| Non-GAAP EBITDA/Total Revenue | 12.5 | % | -2.7 | % | 11.8 | % | -6.7 | % | ||||||||
| NON-GAAP ADJUSTED EBITDA CALCULATION | ||||||||||||||||
| Non-cash compensation | 727 | 840 | 2,892 | 4,117 | ||||||||||||
| Gain on divestiture | (3,281 | ) | — | (3,281 | ) | — | ||||||||||
| Divestiture/acquisition-related expenses | 122 | — | 491 | 338 | ||||||||||||
| Acquisition-related fair value adjustments | 47 | 167 | 358 | 415 | ||||||||||||
| Unrealized foreign currency translation loss (gain) | 206 | 101 | 60 | (5 | ) | |||||||||||
| Separation related expenses | — | 192 | 23 | 682 | ||||||||||||
| Non-GAAP Adjusted EBITDA | $ | 1,862 | $ | 438 | $ | 16,344 | $ | (2,331 | ) | |||||||
| Non-GAAP Adjusted EBITDA/Total Revenue | 5.8 | % | 1.4 | % | 12.2 | % | -2.0 | % | ||||||||